JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Support: [email protected]

Track Your Order

mTOR

C4204 OXA-01

Summary: mTORC1 and mTORC2 inhibitor

≤3 mg/mL
B8001 GNE-477

Summary: dual PI3K/mTOR inhibitor

insoluble in H2O; insoluble in EtOH; ≥16.69 mg/mL
B8000 GNE-493

Summary: Pan-PI3K/mTOR inhibitor

Soluble in DMSO
B6171 CC-223

Summary: mTOR inhibitor, orally bioavailable

insoluble in H2O; ≥108 mg/mL
B5853 MHY1485
2 Citation

Target: mTOR

Summary: mTOR activator, autophage inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.35 mg/mL
B2184 GDC-0980 (RG7422)

Summary: Class I PI3K inhibitor for PI3Kα/β/δ/γ

≥21.35 mg/mL
B1642 WYE-125132 (WYE-132)

Target: mTOR

Summary: ATP-competitive mTOR inhibitor, highly potent

insoluble in EtOH; insoluble in H2O; ≥13 mg/mL
B1641 WAY-600

Target: mTOR

Summary: MTOR inhibitor

≥12.38 mg/mL
B1639 Ridaforolimus (Deforolimus, MK-8669)

Target: mTOR

Summary: MTOR inhibitor

≥49.5 mg/mL
B1638 WYE-687

Summary: MTOR inhibitor,ATP-competitive and selective

insoluble in H2O; insoluble in EtOH; insoluble in DMSO